|
|
 |
|
Viewing report
|
|
|
|
The Top 30 Developers of Molecular Diagnostic Tests for Breast Cancer
Research Facts Ltd, Nov 2010, Pages: 72
According to the WHO’s International Agency for Research on Cancer’s most recent estimates, breast cancer is by far the most frequent cancer among women with an estimated 1.38 million new cancer cases diagnosed in 2008 (23% of all cancers). In that year, it was the most common women’s cancer both in developed and developing regions with around 690,000 new cases estimated in each region.
Incidence rates vary from 19.3 per 100,000 women in Eastern Africa to 89.9 per 100,000 women in Western Europe, and are high (greater than 80 per 100,000) in developed regions of the world (except Japan) and low (less than 40 per 100,000) in most of the developing regions.
The range of mortality rates is much less (approximately 6-19 per 100,000) because of the more favourable survival of breast cancer patients in (high-incidence) developed regions. As a result, breast cancer ranked as the fifth most common cause of death from cancer overall in 2008 (458,000 deaths), but it was still the most frequent cause of cancer death in women.
Consequently, there is a tremendous need for molecular diagnostic tests for breast cancer screening, diagnosis, therapy selection and relapse monitoring. This report profiles the top 30 developers of such tests.
Profile information for each company in The Top 30 Developers of Molecular Diagnostic Tests For Breast Cancer typically includes:
- Company Contact Information - Address, Telephone and Fax Numbers, Email and Website Address
- Key Company Decision Makers - From CEO and Main Board, to Key Senior Managers
- Specialised fields such as Company Description, Ownership, Products, Technology, Year Established, Number of Employees, Turnover and Foreign Trade.
Report Target Market:
1) Molecular Diagnostics Companies
Usage: competitive/financial analysis and strategic partner/alliance identification.
2) Suppliers To Molecular Diagnostics Companies
The Top 30 Developers of Molecular Diagnostic Tests For Breast Cancer is ideal for suppliers who wish to identify top potential customers.
3) In Vitro Diagnostics Importing & Distribution Companies
This report is invaluable to distributors in sourcing all the leading breast cancer molecular diagnostic tests.
4) Pharmaceutical & Biotechnology Companies
This report is very useful to those pharmaceutical and biotechnology companies that are interested in pharmacogenomics and developing personalised medicines.
Note: Most people will be aware of some of the major developers of molecular diagnostic tests for breast cancer such as Agendia, Clarient and Myriad but this report looks at all 30 of the top developers of such tests - companies like:
Nuvera Biosciences, Inc. - the Massachusetts, United States based company is focused on developing novel molecular diagnostics that make a significant impact on cancer care by improving detection techniques and treatment selection in cancer. Nuvera’s initial offering is aimed at differentiation and selection of treatments in breast cancer leading to higher response from chemotherapy and endocrine therapy and better rates of survival among treated patients.
DiaGenic ASA - named Norway’s Most Innovative Company in 2009, DiaGenic is currently in the process of establishing a distribution network for its breast cancer test, BCtect®.
Report data field structure is as follows:
- Company Name
- Mailing Address
- Street Address
- Telephone
- Fax
- Email
- Website
- Parent Company Name
- Year Established
- Number of Employees
- Key Executives
- Company Description
- Products
- Technology
- Turnover €m
- Foreign Trade
- Location Status
- Ownership
Research Facts’ reports help you make informed decisions about the markets and organisations that affect your business.
- Learn more about your target markets and target companies
- Top level research on all the major players in a market
- See which organisations dominate your major markets
- Get detailed information on particular organisations
Research Facts is a world leader in healthcare and life sciences publishing. It was established in Dublin, Ireland in 2004. Its partners have over forty years combined experience in the business information industry. Research Facts’ customers include most of the world’s major diagnostics, pharmaceutical, biotechnology and medical device companies e.g. Roche, Abbott Molecular, Johnson & Johnson, Wyeth, Dako Denmark, Medtronic, Philips Healthcare, HemoCue, Thermo Fisher Scientific, Smith & Nephew, Covance, Future Diagnostics, GE Healthcare, Ipsen, Edwards Lifesciences, B Braun, Orion Diagnostica, Teva, Biomet, Boehringer Ingelheim, Siemens Healthcare Diagnostics, DePuy, Bayer, Qiagen, Intuitive Surgical, LifeScan etc..
Research Facts has customers right across the globe e.g. Australia, Belgium, Brazil, Canada, Cyprus, Denmark, France, Germany, Finland, Hungary, India, Ireland, Israel, Italy, Japan, Korea, Luxembourg, Mauritius, Netherlands, Pakistan, Portugal, Russia, Saudi Arabia, Slovenia, South Africa, Spain, Sweden, Switzerland, United Kingdom, and United States.
Keywords: Molecular Diagnostics, Breast Cancer.
Customers who bought this item also bought
Molecular Diagnostics: Market Segmentation and Opportunities - 4th Edition
Personalized Medicine - Scientific and Commercial Aspects
The Top 20 Developers of Molecular Diagnostic Tests for Lung Cancer
Molecular Diagnostics in Cancer Testing
Innovations in Oncology Diagnostics: Technological Advances, Growth Opportunities and Future Market Outlook
Biomarker Technology Platforms for Cancer Diagnoses and Therapies
Cytology and HPV Testing World Markets
Cancer Diagnostic Testing World Markets
Innovations in Cancer: Novel Therapeutics, New Diagnostics and Future R&D Strategies
Advancing Molecular Diagnostics to Personalize Cancer Therapy
|
|
|
|
